Larvol Delta

milatuzumab (IMMU-115) - Immunomedics

Immunomedics: Commercial Update (Immunomedics) - Jul 23, 2016 - Anticipated patent expiry in US, Europe and Japan between 2023 and 2024
Anticipated patent expiry • Graft versus Host Disease

http://www.immunomedics.com/partnering5-demo.shtml

Jul 23, 2016